Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis

Ran Ren; Pengpeng Yin; Yan Zhang; Jianyun Zhou; Yixing Zhou; Rufu Xu; Hai Lin; Chunji Huang

doi:10.18632/oncotarget.12707

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis

Ran Ren, Pengpeng Yin, Yan Zhang, Jianyun Zhou, Yixing Zhou, Rufu Xu, Hai Lin _ and Chunji Huang

PDF | HTML | How to cite

Oncotarget. 2016; 7:84851-84859. https://doi.org/10.18632/oncotarget.12707

Metrics: PDF 1915 views | HTML 2405 views | ?

Abstract

Ran Ren1,*, Pengpeng Yin1,*, Yan Zhang1,*, Jianyun Zhou1, Yixing Zhou1, Rufu Xu1, Hai Lin2, Chunji Huang2

1Division of Scientific Research, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China

2Department of Scientific Research, Third Military Medical University, Chongqing, 400038, China

*These authors have contributed equally to this work

Correspondence to:

Hai Lin, email: [email protected]

Chunji Huang, email: [email protected]

Keywords: Fibulin-3, malignant pleural mesothelioma, diagnostic value, meta-analysis, systematic review

Received: September 08, 2016 Accepted: October 01, 2016 Published: October 17, 2016

ABSTRACT

Background: Several studies have investigated the diagnostic value of fibulin-3 for malignant pleural mesothelioma (MPM), but the results were various. Therefore, we performed a systematic review and meta-analysis to evaluate the diagnostic value of fibulin-3 for MPM.

Results: Eight studies were included in this work. The overall sensitivity of blood fibulin-3 were 0.87 (95% CI, 0.58 – 0.97) and 0.89 (95% CI, 0.77 – 0.95), respectively. The overall sensitivity and specificity of PF fibulin-3 for MPM were 0.73 (95% CI, 0.54 – 0.86) and 0.80 (95% CI, 0.60 – 0.91), respectively. The area under curve of blood and pleural effusion (PF) Fibulin-3 were 0.94 (95% CI, 0.91 – 0.96) 0.83 (95% CI, 0.79 – 0.86), respectively.

Methods: PubMed and EMBASE databases were searched up to July 29, 2016 to verify studies investigating the diagnostic value of fibulin-3 for MPM. The quality of eligible studies was assessed using the revised Quality Assessment for Studies of Diagnostic Accuracy tool (QUADAS-2). The overall sensitivity and specificity were pooled using a bivariate model.

Conclusion: Fibuoin-3 is a useful diagnostic marker for MPM.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12707

Publication Alerts

Research Papers:

Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis

Abstract